Item 2.02 Results of Operations and Financial Condition.

On January 9, 2023, Dynavax Technologies Corporation ("Dynavax") issued a press release announcing its preliminary unaudited fourth quarter and full year 2022 financial highlights. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K, and is incorporated herein by reference.

The preliminary selected financial results included in the press release are based upon estimates and information available as of the date of the press release. Accordingly, undue reliance should not be placed on these preliminary estimates. In addition, the Company has not yet completed its financial close process for the quarter and year ended December 31, 2022, therefore the estimates included in the press release regarding net product revenue and cash and cash equivalents, and marketable securities are preliminary, unaudited and are subject to change upon completion of the Company's financial statement closing procedures and the audit of the Company's consolidated financial statements.

Item 7.01 Regulation FD Disclosure.

The press release issued by the Company on January 9, 2023, and attached as Exhibit 99.1 to this current report also reported phase 1 shingles topline results.

The Company has posted a presentation (the "Presentation") to its website at www.dynavax.com, in the "Events & Presentations" subsection of the "News & Events" tab. A copy of the Presentation is attached as Exhibit 99.2 to this current report and is incorporated herein by reference.

All of the information furnished in this Form 8-K, including the accompanying Exhibits 99.1 and 99.2, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this current report and in the accompanying exhibit shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by Dynavax, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits. The following exhibit is furnished herewith:

99.1 Press release dated January 9, 2023 titled "Dynavax Announces Preliminary

Unaudited Fourth Quarter and Full Year 2022 Financial Highlights and Phase 1


     Shingles Topline Results".
99.2   Dynavax Investor Presentation
104  Cover Page Interactive Data File (embedded within the Inline XBRL document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses